Business Wire

CGTN: China Makes Proposals for UN's Role in Post-Pandemic Era

22.9.2020 09:48:00 EEST | Business Wire | Press release

Share

The United Nations, beginning with 51 signatories at the end of World War II, has now grown to be a 193-nation body. As it celebrates its 75th founding anniversary, the organization and multilateralism it represents are facing unprecedented challenges with the rise of unilateralism and protectionism.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200921005948/en/

The challenges are being compounded by COVID-19, which has infected more than 31 million people and taken over 960,000 lives worldwide.

"What kind of UN does the world need and what role should it play in the post-pandemic era?"

Chinese President Xi Jinping raised the question and made proposals on Monday when addressing the high-level meeting to commemorate the 75th anniversary of the UN via video link.

The UN should uphold justice as countries, regardless of their sizes, are equal and should respect each other, Xi said, noting that this is a requirement of the progress of the times and the most important principle in the UN Charter.

The organization should be committed to achieving shared growth through consultation and collaboration, he stressed, calling on countries around the world to maintain common security and share the fruits of development.

Xi called for increased representation and a louder voice for developing countries in the UN and upholding the purposes and principles of the UN Charter.

He said the UN should promote international cooperation and lead efforts to solve various problems in the world. It should advance security, development and human rights in a balanced manner and give more emphasis to development on its global agenda, he added.

Uphold multilateralism, enhance cooperation

"During the 75 years of the UN, the world has seen rapid progress of the human society, profound changes in international situations and fast development of multilateralism," the Chinese president said.

He reiterated China's commitment to multilateralism and determination to safeguard the international system with the UN at its core.

As the international community strives to find solutions to problems faced by mankind, "multilateralism" has been a buzzword during the 75th session of the UN General Assembly that opened last week.

UN Secretary-General Antonio Guterres urged world leaders to work together at a time when there is a surplus of multilateral challenges and a deficit of solutions. "The future we want, the United Nations we need, is reaffirming our collective commitment to multilateralism is under way," he said.

Indeed, the need for more – and more effective – multilateralism is well known, he said, stressing that national sovereignty – a pillar of the Charter of the United Nations – goes hand‑in‑hand with enhanced international cooperation, based on common values and shared responsibilities for progress.

Russian Foreign Minister Sergei Lavrov said the international community is becoming increasingly fragmented, adding that "this is largely attributable to the fact that some countries are meddling in the domestic affairs of other states and imposing unilateral sanctions."

"The world is tired of dividing lines, of separating states into friends and foes, and demands stepping up all-encompassing and inclusive mutual assistance and cooperation," he said.

German Chancellor Angela Merkel said the interests of individual member states had "too often" forced the UN to lag behind its ideals.

"Those who believe that they can get along better alone are mistaken. Our well-being is something that we share – our suffering too. We are one world," she told the General Assembly.

While customs and cultures may differ, cooperation requires unstinting efforts to overcome misunderstanding, and beyond that, to embrace respect, European Council President Charles Michel noted.

"It is not our rhetoric that will matter," he said, but rather, the collective actions taken to foster a better world.

The theme of this year's UN high-level sessions is "The Future We Want, the UN We Need: Reaffirming Our Collective Commitment to Multilateralism." It echoes Xi's consistent call to build a community with a shared future for mankind.

Meanwhile, 48 former UN and government officials from around the world released an open letter – "A Time for Renewal: Calling for a Strengthened Multilateral System" – last Friday, expressing their hope that the UN would be transformed into a "stronger, more accountable, inclusive multilateral system."

"There is an urgent need for an explicit recognition by global leaders that we are at a turning point and must act decisively to defend and rejuvenate multilateralism," they said, stressing that recovery from the COVID-19 pandemic needs national leadership and effective global cooperation.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Jiang Simin
jiang.simin@cgtn.com
+86 18826553286

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release

PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release

Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we

Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release

Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release

Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye